

Disclosure of received notification

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notification.

Notification of Alychlo NV and Marc Coucke, received on 13 September 2017

- On 13 September, Fagron received a notification that the shareholding of Alychlo NV and Marc Coucke, a parent undertaking or a controlling person, had fallen below the disclosure threshold of 15% on 5 September as the result of the disposal of voting securities or voting rights.
- On the notification date, Alychlo NV and Marc Coucke held a total of 10,749,267 voting rights. 10,742,220 voting rights were held by Alychlo NV and 7,047 voting rights were held by Marc Coucke.
- Based on the denominator of 71,843,904 (total number of voting rights), in total Alychlo NV and Marc Coucke held on the notification date 14.96% of the total number of voting rights.
- Alychlo NV is controlled by Marc Coucke.
- The notification of Alychlo NV and Marc Coucke can be viewed on investors.fagron.com via this [link](#).

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

For more information:

Constantijn van Rietschoten
Chief Communications Officer
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com

Fagron profile

Fagron is the leading global pharmaceutical compounding company, bringing customized pharmaceutical care to hospitals, pharmacies, clinics and patients in 34 countries worldwide.

The Belgian company Fagron NV is located in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

¹ This press release was sent out by Fagron NV and Fagron BV.

